

selected publications 2011-2017 Catherine LUBETZKI

Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, de Sèze J, Taithe F, Clavelou P, Bourre B, Delvaux V, Rico A, Labauge P, Tourbah A, Lebrun C, Pelletier J, Moreau T, Louapre C, **Lubetzki C**, Papeix C. Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome. **Neurol Neuroimmunol Neuroinflamm.** 2017 Apr 14;4(3):e346. doi: 10.1212/NXI.0000000000000346. eCollection 2017 May.

Bodini B, Branzoli F, Poirion E, García-Lorenzo D, Didier M, Maillart E, Socha J, Bera G, **Lubetzki C**, Ronen I, Lehericy S, Stankoff B. Dysregulation of energy metabolism in multiple sclerosis measured in vivo with diffusion-weighted spectroscopy. **Mult Scler.** 2017 Apr 1:1352458517698249. doi: 10.1177/1352458517698249. [Epub ahead of print]

Sidhom Y, Maillart E, Tezenas du Montcel S, Kacem I, **Lubetzki C**, Gouider R, and Papeix C. Fast multiple sclerosis progression in North Africans: both genetics and environment matter. **Neurology** 2017, Mar 28;88(13):1218-1225

Stankoff B, Jadasz JJ, Hartung HP, Küry P, Zalc B, **Lubetzki C**. Repair strategies for multiple sclerosis: challenges, achievements and perspectives. **Curr Opin Neurol.** 2016 Jun;29(3):286-92.

Papeix C, Vukusic S, Casey R, Debard N, Stankoff B, Mrejen S, Uhry Z, Van Ganse E, Castot A, Clanet M, **Lubetzki C**, Confavreux C; TYSEDMUS and OFSEP Group. Risk of relapse after natalizumab withdrawal: Results from the French TYSEDMUS cohort. **Neurol Neuroimmunol Neuroinflamm.** 2016 Oct 28;3(6):e297. eCollection 2016 Dec.

Clark KC, Josephson A, Benusa SD, Hartley RK, Baer M, Thummala S, Joslyn M, Sword BA, Elford H, Oh U, Dilsizoglu-Senol A, **Lubetzki C**, Davenne M, DeVries GH, Dupree JL. Compromised axon initial segment integrity in EAE is preceded by microglial reactivity and contact. **Glia.** 2016 Jul;64(7):1190-209. doi: 10.1002/glia.22991.

Lublin F, Miller DH, Freedman MS, Cree BA, Wolinsky JS, Weiner H, **Lubetzki C**, Hartung HP, Montalban X, Uitdehaag BM, Merschhemke M, Li B, Putzki N, Liu FC, Häring DA, Kappos L; INFORMS study investigators.. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. **Lancet.** 2016 Mar 12;387(10023):1075-84

Moyon S, Huynh JL, Dutta D, Zhang F, Ma D, Yoo S, Lawrence R, Wegner M, John GR, Emery B, **Lubetzki C**, Franklin RJ, Fan G, Zhu J, Dupree JL, Casaccia P. Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage. **Cell Rep.** 2016 Apr 13. pii: S2211-1247(16)30331-X.

Bodini B, Veronese M, García-Lorenzo D, Battaglini M, Poirion E, Chardain A, Freeman L, Louapre C, Tchikviladze M, Papeix C, Dollé F, Zalc B, **Lubetzki C**, Bottlaender M, Turkheimer F, Stankoff B Dynamic imaging of individual remyelination profiles in multiple sclerosis.. **Ann Neurol.** 2016 Feb 18. doi: 10.1002/ana.24620.

Moyon S, Dubessy AL, Aigrot MS, Trotter M, Huang JK, Dauphinot L, Potier MC, Kerninon C, Melik Parsadaniantz S, Franklin RJ, **Lubetzki C**. Demyelination causes adult CNS progenitors to revert to an immature state and express immune cues that support their migration. **J Neurosci.** 2015 Jan 7;35(1):4-20.

Freeman SA, Desmazières A, Simonnet J, Gatta M, Pfeiffer F, Aigrot MS, Rappeneau Q, Guerreiro S, Michel PP, Yanagawa Y, Barbin G, Brophy PJ, Fricker D, **Lubetzki C***, Sol-Foulon N*. Acceleration of conduction velocity linked to clustering of nodal components precedes myelination. **Proc Natl Acad Sci U S A.** 2015 Jan 20;112(3):E321-8.

Tepavčević V, Kerninon C, Aigrot MS, Meppiel E, Mozafari S, Arnould-Laurent R, Ravassard P, Kennedy TE, Nait-Oumesmar B, **Lubetzki C**. Early netrin-1 expression impairs central nervous system remyelination. **Ann Neurol.** 2014 Aug;76(2):252-68.

Piaton G, Aigrot MS, Williams A, Moyon S, Tepavcevic V, Moutkine I, Gras J, Matho KS, Schmitt A, Soellner H, Huber AB, Ravassard P, **Lubetzki C**. Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system. **Brain.** 2011 Apr;134(Pt 4):1156-67.

Stankoff B, Freeman L, Aigrot MS, Chardain A, Dollé F, Williams A, Galanaud D, Armand L, Lehericy S, **Lubetzki C**, Zalc B, Bottlaender M Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole. **Ann Neurol.** 2011 Apr;69(4):673-80. doi: 10.1002/ana.2232